News

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

2015-09-24

On September 21st, 2015, Wuxi Municipal Committee and Wuxi Municipal People’s Government hold the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”, which aims to expand the international perspective for Wuxi industrial development. Jiangsu ProteLight ‘s President Dr. Yuxin Chen, and Chief technical consultant Dr. Hartmut Michel were invited to attend the meeting and made speech there.

(2nd from right) Chairman Dr. Chen Yuxin, (3rd from right) Dr. Hartmut Michel, Chief Technical Advisor

Previous article

Our New Technology Got U.S. Invention Patent License

Next article

ProteLight’s PL-5 was listed in Priority Review Varieties

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China